Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
PROCEPT BioRobotics Corp. (PRCT)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$21.66+7.39%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for PRCT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Limit adjusted EBITDA loss to $17M-$30M in 2026 | Management plans to reduce adjusted EBITDA loss to between $17M and $30M. | Broken | Adjusted EBITDA loss exceeds $30M in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 3 supplied quarters. Management reported: “Adjusted EBITDA* was a loss of $9.8 million for the third quarter of 2026, compared to a loss of $7.4 million in the prior year period.” “For more information about the Company’s use of non-GAAP financial measures, please see the section below titled “Use of Non-GAAP Financial Measures (Unaudited).” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-growth medical technology business with a loss-making profile, rather than an established profit compounder. The multi-year view is on watch: management is meeting several stated goals, but recent financial performance has lagged its industry cohort.
PRCT trades at a meaningful premium to peers, and the valuation model shows a negative expectations gap, meaning expectations appear demanding relative to the evidence. The pricing tag is justified and no fragility signals were flagged, but the premium leaves limited room for execution to weaken.
Near term, revenue growth and gross margins are tracking management’s 2026 goals, while adjusted EBITDA losses improved from the first quarter to the second. The company remains loss-making, and recent performance is weak; the next results matter because the evidence points to elevated risk of a miss.
The near-term test is whether management maintains its reaffirmed 2026 guidance and continues to narrow adjusted EBITDA losses. A guidance cut or a weaker jobs backdrop would add pressure, while continued strong results and guidance from large healthcare peers could support sector momentum.
Over the next 1 to 3 years, the thesis depends on sustained growth, stable margins, and progress toward lower losses, against a premium valuation and recent underperformance. The evidence is mixed, so execution remains central to the multi-year view. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Maintain 65% gross margin in 2026 | It targets a stable 65% gross margin. | Intact | Gross margin falls below 60% in FY26 | Gross margin: 66.28% FY2026-Q3; GAAP. Published target: 65%. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 202666.280738 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 3 supplied quarters. Management reported: “U.S. average selling price was approximately $495,000 for new HYDROS systems • U.S. handpieces sold as percent of U.S. procedures in the third quarter of 2026 was approximately 106% • Third quarter of 2026 handpiece average selling price of approximately $3,570 increased 12% compared to the third quarter of 2025 • International revenue of $12.5 million for the third quarter of 2026, an increase of 32% compared to the prior year period • Gross margin of 66% for the third quarter of 2026, compared to 65% in the prior year period.” “For more information about the Company’s use of non-GAAP financial measures, please see the section below titled “Use of Non-GAAP Financial Measures (Unaudited).” Delivery assessment Nov 4, 2026 |
Achieve $390M-$410M revenue in 2026 | A primary condition in PROCEPT BioRobotics Corp.'s published investment case. The stated target is ~$400M. | Intact | Annual revenue falls below $325M in 2026 | Revenue: $98.291M FY2026-Q3; GAAP. Published target: ~$400M. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 202698,291,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 3 supplied quarters. Management reported: “Third Quarter 2026 Financial Results • Total revenue of $98.3 million for the third quarter of 2026, an increase of 18% compared to the prior year period in 2025 • U.S. procedures over 13,400 for the third quarter of 2026, an increase of approximately 22% compared to the prior year period • Delivered 62 U.S. HYDROS systems, which included 20 replacement systems.” ““Further, we remain excited to present data from WATER IV, our randomized trial comparing Aquablation to radical prostatectomy in prostate cancer, on track for the first half of 2027.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.89 → $-1.15 · observed estimates
$0.49B → $0.48B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.89 | $490,489,830 | 10 / 13 |
| 2026-07-25 | $-0.89 | $490,489,830 | 10 / 13 |
| 2026-07-26 | $-0.89 | $490,489,830 | 10 / 13 |
| 2026-07-27 | $-0.89 | $490,489,830 | 10 / 13 |
| 2026-07-28 | $-0.89 | $490,489,830 | 10 / 13 |
| 2026-07-29 | $-0.90 | $490,129,050 | 11 / 14 |
| 2026-07-30 | $-0.89 | $490,489,628 | 8 / 9 |
| 2026-07-31 | $-0.90 | $490,128,868 | 9 / 10 |
| 2026-08-01 | $-0.90 | $490,128,868 | 9 / 10 |
| 2026-08-02 | $-0.90 | $490,129,050 | 11 / 14 |
| 2026-08-03 | $-0.90 | $490,127,682 | 9 / 10 |
| 2026-08-04 | $-0.90 | $490,127,682 | 9 / 10 |
| 2026-08-05 | $-0.90 | $490,127,682 | 9 / 10 |
| 2026-08-06 | $-0.90 | $490,127,682 | 9 / 10 |
| 2026-08-07 | $-1.11 | $478,269,346 | 9 / 10 |
| 2026-08-08 | $-1.15 | $476,838,470 | 11 / 14 |
| 2026-08-09 | $-1.15 | $476,838,470 | 11 / 14 |
| 2026-08-10 | $-1.11 | $478,269,346 | 9 / 10 |
| 2026-08-12 | $-1.15 | $476,838,470 | 11 / 14 |
| 2026-08-13 | $-1.11 | $478,269,346 | 9 / 10 |
| 2026-08-14 | $-1.11 | $478,269,346 | 9 / 10 |
| 2026-08-15 | $-1.11 | $478,269,346 | 9 / 10 |
| 2026-08-16 | $-1.11 | $478,269,346 | 9 / 10 |
| 2026-08-17 | $-1.11 | $478,269,346 | 9 / 10 |
| 2026-08-18 | $-1.11 | $478,269,346 | 9 / 10 |
| 2026-08-19 | $-1.11 | $478,269,346 | 9 / 10 |
| 2026-08-20 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-08-21 | $-1.14 | $476,976,474 | 9 / 10 |
| 2026-08-22 | $-1.14 | $476,976,474 | 9 / 10 |
| 2026-08-23 | $-1.14 | $476,976,474 | 9 / 10 |
| 2026-08-24 | $-1.14 | $476,976,474 | 9 / 10 |
| 2026-08-25 | $-1.14 | $476,976,474 | 9 / 10 |
| 2026-08-26 | $-1.14 | $476,976,474 | 9 / 10 |
| 2026-08-27 | $-1.14 | $476,976,474 | 9 / 10 |
| 2026-08-28 | $-1.14 | $476,976,474 | 9 / 10 |
| 2026-08-29 | $-1.14 | $476,976,474 | 9 / 10 |
| 2026-08-30 | $-1.14 | $476,976,474 | 9 / 10 |
| 2026-08-31 | $-1.14 | $476,976,474 | 9 / 10 |
| 2026-09-01 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-02 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-03 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-04 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-05 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-06 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-07 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-08 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-09 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-10 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-11 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-12 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-13 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-14 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-15 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-16 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-17 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-18 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-19 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-20 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-21 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-22 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-23 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-24 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-25 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-26 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-27 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-28 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-29 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-09-30 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-10-01 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-10-02 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-10-03 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-10-04 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-10-05 | $-1.14 | $476,978,903 | 9 / 10 |
| 2026-10-06 | $-1.13 | $476,764,617 | 9 / 10 |
| 2026-10-07 | $-1.15 | $476,764,617 | 9 / 10 |
| 2026-10-08 | $-1.15 | $476,764,617 | 9 / 10 |
| 2026-10-09 | $-1.15 | $476,764,617 | 9 / 10 |
| 2026-10-10 | $-1.15 | $476,764,617 | 9 / 10 |
| 2026-10-11 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-10-12 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-10-13 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-10-14 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-10-15 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-10-16 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-10-17 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-10-18 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-10-19 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-10-20 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-10-21 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-10-22 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-10-23 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-10-24 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-10-25 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-10-26 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-10-27 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-10-28 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-10-29 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-10-30 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-10-31 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-11-01 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-11-02 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-11-03 | $-1.15 | $476,371,760 | 9 / 10 |
| 2026-11-04 | $-1.15 | $476,371,760 | 9 / 10 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 5 Buy / Strong Buy · 9 Hold · 1 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.